<DOC>
	<DOC>NCT01145859</DOC>
	<brief_summary>The first study with rivaroxaban in pediatric subjects is a Phase I study, where the pharmacokinetic/pharmacodynamic (PK/PD) profile of rivaroxaban will be investigated to confirm that the exposure is comparable to adults. This study is a single dose study with multiple PK/PD measurements in pediatric subjects at the end of their Venous Thromboembolism (VTE) treatment.</brief_summary>
	<brief_title>Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Pediatric subjects &gt; 6 months and &lt; 18 years of age at the time of administration of study drug. Patients who have completed treatment of VTE, but are considered to have risk for recurrence of VTE Any major or clinically relevant bleeding during prior VTE treatment Abnormal coagulation tests within 7 days prior to study drug administration Severe renal impairment Planned invasive procedures prior to or after 24 hours of study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Pediatrics</keyword>
</DOC>